Novartis has deepened its collaboration with Monte Rosa Therapeutics by agreeing on a new partnership worth up to $5.7 billion to develop multiple molecular glue degraders targeting immune-mediated diseases. Monte Rosa will perform discovery and early development, with Novartis advancing licensed programs. This broad collaboration expands on their previous agreement and highlights Novartis’ commitment to innovative protein degradation therapies addressing high unmet needs in immunology.